<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00317031</url>
  </required_header>
  <id_info>
    <org_study_id>PREDICT</org_study_id>
    <nct_id>NCT00317031</nct_id>
  </id_info>
  <brief_title>Individually Adapted Therapy of Alcoholism</brief_title>
  <official_title>Individually Adapted Therapy of Alcoholism: Clinical Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Institute of Mental Health, Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dupont Applied Biosciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Institute of Mental Health, Mannheim</source>
  <brief_summary>
    <textblock>
      The primary objective is to directly compare the efficacy of acamprosate, naltrexone and&#xD;
      placebo for relapse prevention in alcoholics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to directly compare the efficacy of acamprosate, naltrexone and&#xD;
      placebo for relapse prevention in alcoholics. The secondary objective is to establish an&#xD;
      association between patients' motivational type and drug effects. The aim is to improve&#xD;
      alcoholism treatment by identifying characteristics for response to specific pharmacological&#xD;
      relapse prevention. Such items could allow for an individually adapted pharmacotherapy of&#xD;
      alcoholism. Specifically, we will study the possible dependence of the efficacy of naltrexone&#xD;
      and/or acamprosate on different motivational types (reward versus relief craving) and genetic&#xD;
      profiles referring to glutamatergic and opioidergic candidate genes. Lastly, the longterm&#xD;
      costs and cost-effectiveness of the different treatment strategies for alcoholics chosen in&#xD;
      our study are established.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to relapse to heavy drinking (consumption of more than 48 gram alcohol/day for females and more than 60 gram alcohol/day for males)</measure>
    <time_frame>06/2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of days without heavy drinking (consumption of more than 48 gram alcohol/day for females and more than 60 gram alcohol/day for males)</measure>
    <time_frame>06/2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to first alcohol consumption</measure>
    <time_frame>06/2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of days of complete abstinence from alcohol</measure>
    <time_frame>06/2008</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">435</enrollment>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acamprosate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naltrexone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acamprosate or Naltrexone</intervention_name>
    <description>mg&amp;d 90 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants will have a current DSM-IV/ICD 10 diagnosis of alcohol dependence.&#xD;
&#xD;
          2. Participants must have had a minimum of 14 drinks (females) or 21 drinks (males) on&#xD;
             average per week over a consecutive 30-day period in the 90-day period prior to&#xD;
             initiation of abstinence, and must have had two or more days of heavy drinking&#xD;
             (defined as 4 drinks for females and 5 drinks for males) in the 90-day period prior to&#xD;
             initiation of abstinence.&#xD;
&#xD;
          3. Participants must have had a minimum of 72 hours of abstinence and no significant&#xD;
             withdrawal symptoms (CIWA &lt; 8) prior to randomization.&#xD;
&#xD;
          4. At least 2 weeks of inpatient treatment.&#xD;
&#xD;
          5. Participants can be abstinent for a maximum of 28 days prior to randomization.&#xD;
&#xD;
          6. Participants are willing not to seek additional psychotherapy during the first 6&#xD;
             months of study except attendance of mutual help groups.&#xD;
&#xD;
          7. Participants have to sign a witnessed declaration of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants who meet current DSM-IV criteria for bipolar disorder, schizophrenia,&#xD;
             bulimia/anorexia, dementia, or a psychological disorder for whom medication is&#xD;
             indicated, but no other Axis I disorders that are not medicated and are not severe&#xD;
             enough to require medications.&#xD;
&#xD;
          2. Participants who require psychopharmacotherapy.&#xD;
&#xD;
          3. Participants who require therapy with any medications which pose safety issues.&#xD;
&#xD;
          4. Participants with a current abuse of any psychoactive drug and who show a positive&#xD;
             drug test on an urine screen.&#xD;
&#xD;
          5. Participants with a lifetime diagnosis of dependence on any psycho-active drug except&#xD;
             for nicotine or habitual caffeine use.&#xD;
&#xD;
          6. Participants who have significant medical disorders which would increase the potential&#xD;
             risk of the study treatment or interfere with the study participation.&#xD;
&#xD;
          7. Participants with abnormal AST or ALT (more than 5 times the normal level).&#xD;
&#xD;
          8. Participants who are pregnant or nursing infant(s).&#xD;
&#xD;
          9. Women during childbearing years without an effective contraceptive method.&#xD;
&#xD;
         10. Participants developing sensitivity to the study medication.&#xD;
&#xD;
         11. Participants who are illiterate or are unable to read and write German.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl F. Mann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Institute of Mental Health, J5, 68159 Mannheim, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael N. Smolka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Insitute of Mental Health, J5, 68159 Mannheim, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, University of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>BW</state>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>BW</state>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Addictive Behavior und Addiction Medicine, Central Institute of Mental Health</name>
      <address>
        <city>Mannheim</city>
        <state>BW</state>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Psychiatry, University of TÃ¼bingen</name>
      <address>
        <city>Tuebingen</city>
        <state>BW</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>April 19, 2006</study_first_submitted>
  <study_first_submitted_qc>April 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2006</study_first_posted>
  <last_update_submitted>June 26, 2008</last_update_submitted>
  <last_update_submitted_qc>June 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2008</last_update_posted>
  <responsible_party>
    <name_title>Kiefer, Falk</name_title>
    <organization>Central Institute of Mental Health (CIMH), Mannheim</organization>
  </responsible_party>
  <keyword>Alcoholism</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Acamprosate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

